Henry Schein (HSIC)
(Delayed Data from NSDQ)
$71.21 USD
-0.73 (-1.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.21 USD
-0.73 (-1.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth D Momentum B VGM
Zacks News
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.
What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?
by Zacks Equity Research
In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
CONMED's (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Robust scanner shipments and an increase in Invisalign volumes within the teen segment are expected to have contributed to Align Technology's (ALGN) Q4 performance.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.
Here's Why You Should Invest in Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.
Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Here's Why You Should Add Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at the Diagnostics segment.
Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings
by Zacks Equity Research
With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.
SmileDirectClub (SDC) Moves up on New Strategic Actions
by Zacks Equity Research
SmileDirectClub's (SDC) new strategic actions are focused on supporting the key growth initiatives that will generate the highest return on investment.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.
Intuitive Surgical (ISRG) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect strong segmental performance.
Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings
by Zacks Equity Research
With the latest surge in COVID infections due to the more contagious Omicron variant, Abbott (ABT) is expected to report sequentially stronger diagnostics results for the fourth quarter.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from a robust payment accuracy business. However, intense competition remains a woe.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
DaVita's (DVA) New Buyout to Enhance Transplant Experience
by Zacks Equity Research
DaVita (DVA) acquires MedSleuth which will help simplify the kidney transplant process and provide patients greater access to transplantation.
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.